×

Biotech and Pharmaceuticals Medicine

  • *Benralizumab cuts need for oral steroids in severe asthma. LONDON, May 23- AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Data from the 28- week Phase III clinical...

  • LONDON, May 22- AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Data from the 28- week Phase III clinical trial presented at the American Thoracic Society on Monday...

  • May 22- Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study, bringing the U.S. biotech a step closer to launching a potential blockbuster. Ozanimod came Celgene's way following its $7.2 billion acquisition of Receptos Inc in 2015.. William Blair analyst John Sonnier had then estimated that the...

  • May 22- Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study. The drug, ozanimod, succeeded in another late-stage study in February. Celgene said on Monday it expected to file for U.S. marketing application by the end of this...

  • Margaret Chan, director-general of the World Health Organization, traveled to Guinea earlier this month to join the country's president in celebrating the world's first Ebola vaccine. After praising health workers in West Africa for their triumph over the lethal virus, Chan spent the night in the top-tier presidential suite at the beach-side Palm...

  • SEOUL, May 19- A unit of healthcare conglomerate Johnson& Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. Janssen's lawsuit comes about a month after Samsung, an unlisted subsidiary of contract drug maker Samsung BioLogics Co Ltd, said it got U.S....

  • *China's focus more on cutting ballooning healthcare bill. *Some patients resort to buying drugs smuggled into China. NANJING, China, May 19- China is set to publish its first national list of rare diseases, to guide policymakers as part of a broader overhaul to improve diagnoses and speed up drug approvals in the world's second-largest drugs market.

  • What to watch at ASCO cancer conference

    CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.

  • *Sees 2017 adjusted earnings of 4.4 bln- 4.6 bln euros. The family-controlled firm said on Thursday that sales of its performance materials would fall slightly in 2017, after adjusting for currency swings, having previously forecast growth for the division that is the world's leading supplier of liquid crystals ahead of Japan's JNC Corp and DIC Corp..

  • According to the FDA approval letter, the company has until December to submit the full trial data to the agency. Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer. In addition to Tecentriq's approval for bladder cancer patients whose disease has...

  • May 17- A combination of the Merck& Co immunotherapy Keytruda and a different type of drug that also helps the immune system fight cancer from Incyte Corp led to a high rate of durable responses in a small, ongoing study of patients with advanced lung cancer, according to data released on Wednesday. Incyte shares rose more than 6 percent to $128 in post-market...

  • Rahma Warsame of the Mayo Clinic. Results were released Wednesday by the American Society of Clinical Oncology and will be discussed next month at its annual meeting in Chicago. For the study, researchers taped 529 conversations between doctors and patients with various types of cancer at three outpatient clinics— the kind of places chemo often is given— at...

  • *FDA does not cite safety concerns. The FDA had asked for more data before Concert Pharma could proceed with dosing patients in the mid-stage trial, but the agency did not raise any concerns over the safety of Concert's drug, the drug developer said. The FDA will review the company's response within 30 days of submission and, if positive, the trial will be allowed to...

  • *FDA does not cite safety concerns. The FDA had asked for more data before Concert Pharma could proceed with dosing patients in the mid-stage trial, but the agency did not raise any concerns with the safety of Concert's drug, the drug developer said. Concert Pharma's drug, CTP-543, is competing with Aclaris Therapeutics Inc's ATI-50001 to be the first FDA- approved...

  • May 17- Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata, a type of hair loss. The FDA had told Concert Pharma that it could begin the trial, but before dosing patients, the agency had asked for more data, Concert Pharma said, adding that...

  • VA Sec.: On our way for making veterans' health system work again

    Veterans Affairs Secretary David Shulkin discusses the issues facing health care for our country's veterans.

  • May 17- Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata, a type of hair loss.

  • J&J CEO: We have to pay attention to out-of-pocket drug costs

    Alex Gorsky, Johnson & Johnson CEO, speaks with CNBC's Meg Tirrell about the company's pharmaceutical business, drug pricing and health-care reform.

  • J&J plans to seek approval of more than 10 new medicines by 2021

    CNBC's Meg Tirrell reports the latest out of Johnson & Johnson's analyst day including the company's growing pharmaceutical business.

  • Final results from two clinical trials showed leg and foot amputations occurred about twice as often in patients with type 2 diabetes treated with Invokana, known also as canagliflozin, as those given a placebo, the FDA said in an announcement posted on its website. The warnings include a boxed warning, reserved for the most serious possible adverse events, the...